

FOR THE ACUTE TREATMENT OF MIGRAINE AND PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS¹

Nurtec[®] ODT
(rimegepant)
orally disintegrating tablets 75 mg



Nurtec[®] ODT (rimegepant) is the **only preferred oral CGRP receptor antagonist** on the TRICARE Uniform Formulary²

CGRP, calcitonin gene-related peptide; ODT, orally disintegrating tablet.

INDICATION

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding:* It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please see accompanying full Prescribing Information.

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Express Scripts website. TRICARE formulary search. <https://www.express-scripts.com/frontend/open-enrollment/tricare/fst/#/>. Accessed June 10, 2021.

© 2021 Biohaven Pharmaceuticals, Inc. All rights reserved. Nurtec is a registered trademark of Biohaven Pharmaceuticals, Inc. BIOHAVEN and the Biohaven logo are trademarks or registered trademarks of Biohaven Pharmaceuticals, Inc.

US-RIMODT-2100593 06/17/2021

